RNAI-BASED THERAPEUTIC TARGETING FACTOR 12 AS A PROPHYLACTIC TREATMENT FOR THROMBOEMBOLISM by Melquist, Stacey, Almeida, Lauren, Hamilton, Holly, Pei, Tao, Chu, Qili, Hegge, Julia, Milarch, Tracie, Montez, Jessica, Klein, Jason, Andersen, Aaron, Walters, Megan, Chapman, Christine, Doss, Edie, Li, Zhen, Lewis, David, Kanner, Steven

Get full text

Targeting Factor 12 (F12) with a Novel RNAi Delivery Platform As a Prophylactic Treatment for Hereditary Angioedema (HAE) by Melquist, Stacey, Wakefield, Darren, Hamilton, Holly, Chu, Qili, Almeida, Aaron, Almeida, Lauren, Walters, Megan, Montez, Jessica, Hegge, Julia, Klein, Jason, Hazlett, Christine, Milarch, Tracie, Bertin, Stephanie, Andersen, Aaron, Doss, Edie, Schmidt, Rachael, Goth, Linda, Ferger, Sheryl, Rozema, David, Hamilton, James, Lewis, David, Kanner, Steven

Get full text

Abstract 16554: RNA Interference Mediated Apolipoprotein C3 Gene Silencing as a Therapeutic for Hypertriglyceridemia by Wong, So C, Zhu, Rui, Pei, Tao, Hegge, Julia, Hamilton, Holly, Chu, Qili, Schienebeck, Casi, Christensen, Gary, Trilling, Lucas, Briggs, Jeremy, Doss, Edie, Li, Zhen

Get full text

Abstract 17167: Targeting Apolipoprotein(a) With a Novel RNAi Delivery Platform as a Prophylactic Treatment to Reduce Risk of Cardiovascular Events in Individuals With Elevated Lip... by Melquist, Stacey, Wakefield, Darren, Hamilton, Holly, Chapman, Christine, Grondolsky, Jessica, Schienebeck, Casi, Almeida, Lauren, Klas, Crystal, Hagen, Collin, Almeida, Aaron, Hegge, Julia, Chu, Qili, Trubetskoy, Vladimir, Doss, Edie, Hoover-Plow, Jane, Rozema, David, Lewis, David, Kanner, Steven

Get full text

Abstract 17159: Targeting Factor XII (F12) With a Novel RNAi Delivery Platform as a Prophylactic Treatment for Thromboembolism by Melquist, Stacey, Wakefield, Darren, Hamilton, Holly, Chu, Qili, Almeida, Aaron, Almeida, Lauren, Chapman, Christine, Montez, Jessica, Klein, Jason, Hegge, Julia, Zeller, Molly, Walters, Megan, Andersen, Aaron, Milarch, Tracie, Doss, Edie, Rozema, David, Lewis, David, Kanner, Steven

Get full text

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma by Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.

Get full text

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma by Richardson, Paul G., Schlossman, Robert L., Weller, Edie, Hideshima, Teru, Mitsiades, Constantine, Davies, Faith, LeBlanc, Richard, Catley, Laurence P., Doss, Deborah, Kelly, Kathleen, McKenney, Mary, Mechlowicz, Julie, Freeman, Andrea, Deocampo, Reggie, Rich, Rebecca, Ryoo, Joan J., Chauhan, Dharminder, Balinski, Kathe, Zeldis, Jerome, Anderson, Kenneth C.

Get full text

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma by Richardson, Paul G., Blood, Emily, Mitsiades, Constantine S., Jagannath, Sundar, Zeldenrust, Steven R., Alsina, Melissa, Schlossman, Robert L., Rajkumar, S. Vincent, Desikan, K. Raman, Hideshima, Teru, Munshi, Nikhil C., Kelly-Colson, Kathleen, Doss, Deborah, McKenney, Mary L., Gorelik, Svetlana, Warren, Diane, Freeman, Andrea, Rich, Rebecca, Wu, Anfang, Olesnyckyj, Marta, Wride, Kenton, Dalton, William S., Zeldis, Jerome, Knight, Robert, Weller, Edie, Anderson, Kenneth C.

Get full text

T-cell–depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect by Alyea, Edwin, Weller, Edie, Schlossman, Robert, Canning, Christine, Webb, Iain, Doss, Deborah, Mauch, Peter, Marcus, Karen, Fisher, David, Freeman, Andrea, Parikh, Bijal, Gribben, John, Soiffer, Robert, Ritz, Jerome, Anderson, Kenneth

Get full text

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study by Richardson, Paul G, Lonial, Sagar, Jakubowiak, Andrzej J, Jagannath, Sundar, Raje, Noopur S, Avigan, David E, Ghobrial, Irene, Schlossman, Robert L, Mazumder, Amitabha, Munshi, Nikhil C., Laubach, Jacob, Vesole, David, Joyce, Robin, Rosenblatt, Jacalyn, Xie, Wanling, Doss, Deborah, Warren, Diane L., Ittleman, Kate, Revta, Carolyn, Francis, Dixil, Leister, Charles, Kaster, Sarah, Delaney, Carol, Lauria, Marisa, Mitsiades, Constantine S., Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Weller, Edie, Anderson, Kenneth C.

Get full text

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Commentary by LONIAL, Sagar, RICHARDSON, Paul G, HIDESHIMA, Teru, MUNSHI, Nikhil C, KELLY-COLSON, Kathleen, DOSS, Deborah, MCKENNEY, Mary L, GORELIK, Svetlana, WARREN, Diane, FREEMAN, Andrea, RICH, Rebecca, ANFANG WU, BLOOD, Emily, OLESNYCKYJ, Marta, WRIDE, Kenton, DALTON, William S, ZELDIS, Jerome, KNIGHT, Robert, WELLER, Edie, ANDERSON, Kenneth C, MITSIADES, Constantine S, JAGANNATH, Sundar, ZELDENRUST, Steven R, ALSINA, Melissa, SCHLOSSMAN, Robert L, RAJKUMAR, S. Vincent, RAMAN DESIKAN, K

Get full text